Valence-Logo
Beliebt
Anmelden
Loading data for ALKS — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Alkermes

NasdaqGS: ALKS · Echtzeitkurs · USD
49.48
-0.37 (-0.74%)
Zum Schluss: Aug 18, 2026, 8:00 PM
49.30
-0.36%
Vorbörslich: 4:05 AM

Alkermes (ALKS) Stock Price, Analysis & Data

-0.74%

Keine Daten verfügbar

Geldn/a
Marktkapitalisierung8.3 Mrd
Umsatz (TTM)1.67 Mrd
Nettogewinn (TTM)66.12 Mio
Beta0.27
EPS (ttm)0.38
KGV (TTM)130.21
Forward-KGV27.06
KBV (TTM)4.58
KUV (TTM)4.98
Earnings DateOct 28, 2026
Briefn/a
Volumen946,756
Ø Vol. (20D)2,075,738
Eröffnung50.10
Vortagesschluss49.85
Tagesspanne49.46 - 50.42
52-Wk Range25.17 - 55.67
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product cand...

[Mehr lesen]
Branche Drug Manufacturers - Specialty & Generic
Sektor Healthcare
IPO Datum Jul 16, 1991
Mitarbeiter 2,050
Börse NasdaqGS
Tickersymbol ALKS
Website https://www.alkermes.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Alkermes 1.48 Mrd, ein Rückgang von -5.25% im Vergleich zum Vorjahr (1.56 Mrd). Der Gewinn lag bei 241.66 Mio, ein Rückgang von -34.16 %.

Finanzberichte

Gewinnüberraschung

Alkermes hat die Quartalszahlen am Jul 28, 2026 veröffentlicht:
  • Umsatz von n/a verfehlt die Erwartungen um $0, mit -100.00% Rückgang im Jahresvergleich.
  • EPS von 0.7 übertrifft die Erwartungen um 0.41, mit 2.94% Wachstum im Jahresvergleich.

    • Nächste Ergebnisveröffentlichung

    Alkermes wird voraussichtlich die Quartalszahlen veröffentlichen am Oct 28, 2026, vor Börseneröffnung.
    Analysten erwarten einen Umsatz von ... Upgrade
    news image

    vor 6 Tagen · Zacks

    ALKS Stock Rises 27% in 3 Months: Here's What You Should Know

    Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

    news image

    vor 1 Woche · Insider Monkey

    Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?

    It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year ...

    news image

    vor 1 Woche · The Wall Street Journal

    The Race to Come Up With the Next Big Sleep Drug

    The FDA approved the first drug to treat a root cause of narcolepsy, which could help other sleep conditions as well.

    news image

    vor 2 Wochen · Simply Wall St.

    Is Alkermes (ALKS) Priced For Orexin Success Or Too Rich?

    Alkermes stock has delivered a strong 84.5% return over the past year, yet its broader valuation checks suggest the shares are not a straightforward bargain at current levels. The 84.5% one-year gain ...

    news image

    vor 2 Wochen · Simply Wall St.

    Alkermes (ALKS) Reported Mixed Q2 Results, Does It Look Fairly Valued?

    Alkermes (NasdaqGS:ALKS) shares were in focus after the company reported its second quarter 2026 results on July 28, highlighting higher revenue alongside a significantly lower quarterly net income fi...

    Seite 1 von 2